Two-in-One Polymeric NO-Donor Prodrugs Mediate Precision and Synergistic Prostate Cancer Treatment

Bing Zhao, Yuqing Wan, Xiang Zhou, Junmei Zhang, Jiaxin Chen, Jiachen Yang, Yunzhu Liu, Wei Chen, Yinan Zhong, Hongliang QianACS 2023 · DOI

Abstract

Chemotherapy predominates in clinical treatment of prostate cancer (PCa), while irreversible resistance to chemotherapeutics and severe side effects hinder the therapeutic efficacy, especially in castration-resistant PCa (CRPC). Herein, a bombesin (BBN)-decorated two-in-one prodrug (T-NO/E<sub>2</sub>-PMs) incorporating a polymeric nitric oxide (NO) donor and acetal-linked 17β-estradiol (E<sub>2</sub>) in one backbone is developed, aiming to inhibit androgen receptor (AR) expression, reprogram the tumor microenvironment of CRPC, and enhance estradiol-mediated hypoxic CRPC therapy. Following efficient internalization mediated by BBN, T-NO/E<sub>2</sub>-PMs releases estradiol and NO in response to the unique intracellular environments. Both <i>in vitro</i> and <i>in vivo</i> studies demonstrate that the T-NO/E<sub>2</sub>-PMs nano-prodrug along with NO release potently downregulates AR levels to reverse CRPC and further enhances the chemo-sensitization of estradiol to PCa PC-3 cell apoptosis and the inhibition of metastasis. Collectively, this two-in-one nano-prodrug strategy offers a promising platform for construction of advanced nanomedicine to boost the therapeutic efficacy.
BibTeX
@inproceedings{zhao2023two,
  author = {Bing Zhao and Yuqing Wan and Xiang Zhou and Junmei Zhang and Jiaxin Chen and Jiachen Yang and Yunzhu Liu and Wei Chen and Yinan Zhong and Hongliang Qian},
  title = {{Two-in-One Polymeric NO-Donor Prodrugs Mediate Precision and Synergistic Prostate Cancer Treatment}},
  booktitle = {ACS},
  year = {2023},
  doi = {10.1021/acsami.3c04167},
}

Loading related content...

Figure